Abbott Laboratories stock: UBS reiterates a USD 125.00 target for Abbott Laboratories stock
Published on 10/20/2026 at 17:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUBS target remains in focus
- UBS reiterated a Buy rating and a USD 125.00 target on October 19, 2026.
- Abbott reported USD 12.59 billion in second-quarter 2026 revenue, up 13.00 percent year over year.
- Abbott Laboratories stock costs EUR 91.93 at Lang & Schwarz on October 20, 2026 at 7:36 p.m. CEST, 0.25 percent above the Xetra close of EUR 91.70.
On October 19, 2026, UBS reiterated a Buy rating for Abbott Laboratories and set a USD 125.00 price target, according to Investing.com. The target lies 20.89 percent above the USD 103.40 primary-market price at 11:38 a.m. ET on October 20, 2026. At Lang & Schwarz, the stock was trading at EUR 91.93 on October 20, 2026 at 7:36 p.m. CEST, up 0.25 percent versus the Xetra close of EUR 91.70.
Revenue growth supports the case
Abbott's second-quarter 2026 revenue reached USD 12.59 billion, an increase of 13.00 percent from the year-earlier period, while adjusted earnings per share came in at USD 1.31 against a USD 1.28 consensus estimate, MarketBeat reported on October 15, 2026. The revenue comparison gives the UBS target a business backdrop, although the analyst note itself focused on biosimilars and pharmaceutical growth.
Stock position remains measurable
The euro quotation stood between EUR 91.70 and EUR 94.20 during the October 20, 2026 Xetra session, with 271 shares shown in the ABL.DE quote. The primary-market range for Abbott was USD 81.97 to USD 132.03 over 52 weeks as of October 20, 2026, placing the USD 103.40 price 21.68 percent below the high and 26.15 percent above the low.
Abbott's market capitalization was USD 178.9 billion and its price-to-earnings ratio was 33.17 on October 20, 2026. The company operates across medical devices, diagnostics, nutrition and established pharmaceuticals, and its NYSE listing uses the ticker ABT.
How does Abbott compare?
Comparison with peers
Abbott Laboratories: up 0.25 percent versus the Xetra close, price-to-earnings ratio 33.17, market capitalization USD 178.9 billion
Medtronic: up 1.62 percent on October 20, 2026, price-to-earnings ratio 23.21, market capitalization USD 120.6 billion
Boston Scientific: up 1.80 percent on October 20, 2026, price-to-earnings ratio 18.64, market capitalization USD 66.5 billion
Analyst target sets the near-term frame
UBS's USD 125.00 target is below the USD 135.00 objective attributed to TD Cowen in a report dated October 16, 2026, while the latest quarterly figures show revenue growth of 13.00 percent. The combination leaves the market focused on whether Abbott can sustain growth across its medical-device and pharmaceutical businesses.
Abbott Laboratories stock was trading at EUR 91.93 at Lang & Schwarz on October 20, 2026 at 7:36 p.m. CEST, 0.25 percent above the Xetra close of EUR 91.70 on October 20, 2026. The price stood 30.38 percent below the 52-week high in the primary market.
The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.
Abbott Laboratories market data
- Company: Abbott Laboratories
- ISIN: US0028241000
- Ticker: ABT
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 20, 2026, 7:36 p.m. CEST): EUR 91.93
- Change versus Xetra close: plus 0.25 percent
- Xetra close (October 20, 2026): EUR 91.70
- Market capitalization: USD 178.9 billion (as of October 20, 2026)
- 52-week range: USD 81.97-132.03 (as of October 20, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report S&P 500.
